ALK dysregulation drives tumor growth and progression, so inhibiting ALK, alongside other growth‐promoting kinases, has yielded strong response rates.[2, 3, 4, 5, 6] Another class of growth‐targeting kinase inhibitors includes cyclin‐dependent kinase (CDK) inhibitors, such as Palbociclib and Ribociclib, which target CDK4/6, a key regulator of the cell cycle. The gene discussed is ALK; the disease is neoplasm.